Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 01:43PM EDT. Market open.
| Previous Close | 51.74 |
| Open | 51.65 |
| Bid | 51.11 x 100 |
| Ask | 51.18 x 300 |
| Day's Range | 50.36 - 51.85 |
| 52 Week Range | 50.27 - 75.74 |
| Volume | |
| Avg. Volume | 1,756,574 |
| Market Cap | 11.48B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 19.29 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
© 2024 Yahoo. All rights reserved.